@aatisket where did you find the reference to it only works in a 40% subset of adults?
The only mention of 40% I can find easily is on the MSB page about aGVHD which states
Nearly 50% of all allogeneic BMT patients develop aGVHD3. Liver or gastrointestinal involvement occur in up to 40%4 of all patients with aGVHD and are associated with the greatest risk of death, with mortality rates of up to 85%5.
Ann: Key Day 100 Survival Results In P3 GvHD Trial, page-90
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.000(0.00%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1472 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 6760 | 1 |
View Market Depth
| Last trade - 09.51am 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable